# A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

> **NCT01235416** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 57 (actual)

## Conditions studied

- Histologically or Cytologically Documented Solid Tumors

## Interventions

- **DRUG:** AMG 706

## Key facts

- **NCT ID:** NCT01235416
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-04
- **Final completion:** 2010-02
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2011-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235416, "A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01235416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*